**Question:** Hypercalcemia is seen in

A. Primary hyperparathyroidism
B. Chronic kidney disease
C. Familial hypocalciuric hypercalcemia
D. Malignancy

**Correct Answer:** D. Malignancy

**Core Concept:**
Hypercalcemia refers to an elevated level of calcium in the blood, typically above 10.2 mg/dL. Calcium is an essential mineral for bone and nerve function, along with other physiological processes. In the body, calcium levels are tightly regulated by the endocrine system, primarily through the actions of parathyroid hormone (PTH), calcitonin, and renal calcium handling.

**Why the Correct Answer is Right:**
Hypercalcemia can be classified into primary and secondary causes based on the underlying mechanism. In the case of malignancy, the tumor cells often produce excessive amounts of PTH-related protein (PTHrP), which is structurally similar to PTH. PTHrP stimulates bone resorption and renal calcium reabsorption, leading to elevated serum calcium levels. Additionally, malignancy can cause hypercalcemia through increased osteoclast activity, direct release of calcium from bone, or by inducing renal tubular hypercalciuria.

**Why Each Wrong Option is Incorrect:**
A. Primary hyperparathyroidism: This condition results from an overproduction of PTH from one or more hyperactive parathyroid glands, leading to increased calcium absorption and decreased renal calcium excretion. This is different from malignancy, which causes hypercalcemia through PTHrP production.

B. Chronic kidney disease (CKD): CKD can cause secondary hyperparathyroidism, where the decrease in renal function leads to increased PTH production, which in turn increases calcium absorption and reduces renal calcium excretion. However, the correct answer (malignancy) is characterized by PTHrP production rather than PTH.

C. Familial hypocalciuric hypercalcemia: This is a rare genetic disorder where calcium reabsorption in the kidneys is reduced, leading to hypercalcemia. Unlike malignancy, this condition is caused by a genetic defect in renal calcium handling, not PTHrP production.

**Clinical Pearl:**
Hypercalcemia should always be considered in the differential diagnosis for patients presenting with nonspecific symptoms, such as fatigue, weight loss, and confusion. Early recognition and management are crucial, as hypercalcemia can cause severe complications like nephrolithiasis, nephrocalcinosis, and bone disease. Prompt treatment for hypercalcemia includes addressing the underlying cause (e.g., treating the malignancy), hydration, and administering diuretics like furosemide to increase urine calcium excretion and correct the hypercalcemia. In some cases, bisphosphonates (e.g., pamidronate) can be used to decrease bone resorption and prevent complications.